- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02349152
Remifentanil and Glycemic Response in Cardiac Surgery
The Effect of Intraoperative Continuous Remifentanil Infusion on Glycemic Response and Variability in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Prospective, Randomized, Open Label Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Stress-induced hyperglycemia is a well-known phenomena that occurs during cardiopulmonary bypass surgery. Hyperglycemia increases the incidence of major adverse events and mortality in patients undergoing cardiac surgery.
Remifentanil, an ultra-short acting opioid analgesic, has been shown to reduce the stress response to cardiopulmonary bypass when compared to intermittent fentanyl and inhalation anesthesia. This in turn, will reduce the occurence of perioperative hyperglycemia, glycemic variability and insulin requirements in patients undergoing cardiac surgery.
NOTE;
Primary Outcome changed on 06/15/2015-Change Approved by University of Pittsburgh IRB on 06/22/2015- First patient enrolled January 2016.
Primary outcome measure; Percentage of patients with two or more than two intraoperative blood glucose levels more than 180 mg% in both groups will be estimated and the difference in this parameter between the two groups will form the primary outcome measure of this study.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC Presbyterian Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Open cardiac surgery through sternotomy approach (coronary artery bypass, valve surgery, and any other open heart surgeries)
- Surgery with use of cardiopulmonary bypass
- Patients over 18 years of age
- Both female and male genders
- All races
Exclusion Criteria:
- Minimally invasive heart surgery through thoracotomy approach
- Patients receiving regional analgesia such as intrathecal morphine
- Patients undergoing procedures under deep hypothermic circulatory arrest
- Patients with active infections such as acute infective endocarditis
- Emergency surgery
- Patients undergoing transplantations and ventricular assist device insertion
- Patients on any mechanical circulatory support preoperatively
- Patient's refusal
- Allergy to remifentanil
- Positive pregnancy test
- Morbid obesity
- End stage liver and kidney disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Remifentanil group
Half of subjects enrolled will be randomized to the remifentanil group
|
Subjects in the experimental group will receive remifentanil infusion 0.1-0.4ug/kg/minute
before induction of anesthesia and continued until skin closure.
During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.
Other Names:
|
Active Comparator: Fentanyl group
Half of subjects enrolled will be randomized to the fentanyl group
|
Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug.
Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Glucose Values (More Than One ) > 180 mg%
Time Frame: Intraoperative period
|
Percentage of patients with two or more intraoperative blood glucose levels greater than 180 mg/dl. Percentage in both groups will be estimated, then the difference in this statistic will form the primary outcome measure of this study. (Primary Outcome changed on 06/15/2015-Change Approved by University of Pittsburgh IRB on 06/22/2015- First patient enrolled January 2016) |
Intraoperative period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Insulin Requirement
Time Frame: Intraoperative period; Induction to end of surgery
|
Average dose of insulin (Units/ml) calculated for each group in the intraoperative period
|
Intraoperative period; Induction to end of surgery
|
Number of Blood Glucose Values > 180 mg%
Time Frame: Intraoperative period, Induction to end of surgery
|
Blood glucose values that exceed 180 mg% will be counted
|
Intraoperative period, Induction to end of surgery
|
Mean, Peak and Trough Intraoperative Blood Glucose (mg/dl)
Time Frame: Intraoperative period; Induction to end of surgery
|
Blood glucose measured every hour
|
Intraoperative period; Induction to end of surgery
|
Postoperative Blood Glucose
Time Frame: From ICU Admission (After Surgery) Until 24 hours postoperatively
|
Mean and peak blood glucose levels postoperatively
|
From ICU Admission (After Surgery) Until 24 hours postoperatively
|
Total Postoperative Regular Insulin
Time Frame: From ICU Admission (After Surgery) Until 24 hours postoperatively
|
Total units of regular insulin required post-operatively
|
From ICU Admission (After Surgery) Until 24 hours postoperatively
|
Intraoperative Pre-cardiopulmonary Bypass Hemodynamic Stability
Time Frame: induction of anesthesia till systemic heparinization before cardiopulmonary bypass
|
Blood pressure (systolic, diastolic and mean), Heart rate every 5 minutes from induction of anesthesia till systemic heparinization before cardiopulmonary bypass
|
induction of anesthesia till systemic heparinization before cardiopulmonary bypass
|
Stress Hormone Levels-Cortisol (µg/dl)
Time Frame: Perioperative period (Intraoperatively and 8 hours postoperatively)
|
Serum cortisol levels (measured as µg/dl) taken at: Prebypass, cardiopulmonary bypass (2 samples: at start of bypass and end of bypass), postbypass, ICU 8 hours postoperative period
|
Perioperative period (Intraoperatively and 8 hours postoperatively)
|
Inflammatory Mediator Levels, Interleukin-1b, Interleukin 6 and Tumor Necrosis Factor (TNF) (pg/ml)
Time Frame: Perioperative period (Intraoperatively and 8 hours postoperatively)
|
Inflammatory mediator levels, Interleukin-1b (IL-1b), Interleukin 6 (IL-6) and Tumor Necrosis Factor Alpha (TNFa) (all measured in pg/ml) taken at: Prebypass, cardiopulmonary bypass (2 samples:30 min start of bypass (CPB-30) and end of bypass (CPB-END), postbypass, ICU 8 hours postoperative period
|
Perioperative period (Intraoperatively and 8 hours postoperatively)
|
Stress Hormone Levels-ACTH, GH, Glucagon (pg/ml)
Time Frame: Perioperative period (Intraoperatively and 8 hours postoperatively)
|
Adreno-corticotrophic hormone (ACTH), Growth Hormone (GH) and Glucagon (measured as pg/ml) taken at: Prebypass, cardiopulmonary bypass (2 samples: 30 mins after start of bypass (CPB 30) and end of bypass (CPB END), post-bypass and ICU 8 hours postoperative period
|
Perioperative period (Intraoperatively and 8 hours postoperatively)
|
Society of Thoracic Surgery Patient Outcomes
Time Frame: 30 day outcomes
|
Postoperative outcomes collected from the Society of Thoracic Surgery (STS) database.
30 day Mortality (outcome 1) and 30 day Readmission (outcome 2) cerebral vascular accident(outcome 3), prolonged mechanical ventilation (outcome 4), renal failure (outcome 5), atrial fibrillation (outcome 6), cardiac arrest (outcome 7)
|
30 day outcomes
|
Postoperative Pain
Time Frame: Every day 6 hour for 48 hours postoperative period
|
Pain scores; Every day 6 hour for 48 hours postoperative period
|
Every day 6 hour for 48 hours postoperative period
|
Emergence From Anesthesia
Time Frame: Immediate postoperative period until 30 days post-operatively
|
Time to extubation after completion of surgery in the operating room and intensive care unit
|
Immediate postoperative period until 30 days post-operatively
|
Wound Hyperalgesia
Time Frame: 96 hours postoperatively
|
Von frey hair objective testing
|
96 hours postoperatively
|
Development of Chronic Pain
Time Frame: 1, 3, 6 and 12 months after discharge from the hospital
|
Telephonic call Numeric pain scale; Scale is 0-10, with 10 being the highest pain.
|
1, 3, 6 and 12 months after discharge from the hospital
|
Glycemic Variability
Time Frame: From the start of induction till 24 hours postoperatively
|
Coefficient of variation in blood glucose levels.
Denotes how large the fluctuations in blood glucose are.
Higher numbers indicate increased variation.
|
From the start of induction till 24 hours postoperatively
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kathrivel Subramaniam, MD, University of Pittsburgh Medical Center
Publications and helpful links
General Publications
- Doenst T, Wijeysundera D, Karkouti K, Zechner C, Maganti M, Rao V, Borger MA. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2005 Oct;130(4):1144. doi: 10.1016/j.jtcvs.2005.05.049.
- Ihn CH, Joo JD, Choi JW, Kim DW, Jeon YS, Kim YS, Jung HS, Kwon SY. Comparison of stress hormone response, interleukin-6 and anaesthetic characteristics of two anaesthetic techniques: volatile induction and maintenance of anaesthesia using sevoflurane versus total intravenous anaesthesia using propofol and remifentanil. J Int Med Res. 2009 Nov-Dec;37(6):1760-71. doi: 10.1177/147323000903700612.
- Subramaniam B, Lerner A, Novack V, Khabbaz K, Paryente-Wiesmann M, Hess P, Talmor D. Increased glycemic variability in patients with elevated preoperative HbA1C predicts adverse outcomes following coronary artery bypass grafting surgery. Anesth Analg. 2014 Feb;118(2):277-287. doi: 10.1213/ANE.0000000000000100.
- Shinoda T, Murakami W, Takamichi Y, Iizuka H, Tanaka M, Kuwasako Y. Effect of remifentanil infusion rate on stress response in orthopedic surgery using a tourniquet application. BMC Anesthesiol. 2013 Jul 10;13:14. doi: 10.1186/1471-2253-13-14. eCollection 2013.
- Cok OY, Ozkose Z, Pasaoglu H, Yardim S. Glucose response during craniotomy: propofol-remifentanil versus isoflurane-remifentanil. Minerva Anestesiol. 2011 Dec;77(12):1141-8. Epub 2011 May 20.
- Lazar HL, McDonnell M, Chipkin SR, Furnary AP, Engelman RM, Sadhu AR, Bridges CR, Haan CK, Svedjeholm R, Taegtmeyer H, Shemin RJ; Society of Thoracic Surgeons Blood Glucose Guideline Task Force. The Society of Thoracic Surgeons practice guideline series: Blood glucose management during adult cardiac surgery. Ann Thorac Surg. 2009 Feb;87(2):663-9. doi: 10.1016/j.athoracsur.2008.11.011. No abstract available.
- Subramaniam K, Sciortino C, Ruppert K, Monroe A, Esper S, Boisen M, Marquez J, Hayanga H, Badhwar V. Remifentanil and perioperative glycaemic response in cardiac surgery: an open-label randomised trial. Br J Anaesth. 2020 Jun;124(6):684-692. doi: 10.1016/j.bja.2020.01.028. Epub 2020 Apr 2.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Hyperglycemia
- Heart Diseases
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Adjuvants, Anesthesia
- Remifentanil
- Fentanyl
Other Study ID Numbers
- PRO14110258
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperglycemia
-
Mayo ClinicCompletedHospital Hyperglycemia | Post-transplant HyperglycemiaUnited States
-
Zealand University HospitalNot yet recruitingStress Hyperglycemia | Postoperative Hyperglycemia
-
University of CopenhagenUnknownSurgery--Complications | Hyperglycemia Stress | Hyperglycemia Steroid-inducedDenmark
-
University of LeedsCompletedEffect of Food on Postprandial HyperglycemiaUnited Kingdom
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...RecruitingHyperglycemia StressUnited States
-
Loughborough UniversityUniversity of BedfordshireCompletedPostprandial HyperglycemiaUnited Kingdom
-
Centre Hospitalier Universitaire de BesanconEli Lilly and Company; AstraZenecaCompleted
-
Medical University of ViennaCompleted
-
Addis Ababa UniversityCompletedHyperglycemia, Postprandial
-
University of Eastern FinlandFinnsugar LtdCompletedHyperglycemia, PostprandialFinland
Clinical Trials on Remifentanil
-
University Medical Center GroningenCompletedAnesthesia | Hemodynamic Instability | Interaction | Disorder of Oxygen TransportNetherlands
-
Inje UniversityCompletedStrabismusKorea, Republic of
-
Ciusss de L'Est de l'Île de MontréalCompletedIntubation; Difficult or FailedCanada
-
Helse FonnaCompletedAnesthesia, General | Anesthesia, Intravenous | Hemodynamic InstabilityNorway
-
Hopital FochCompletedGeneral AnesthesiaFrance
-
Capital Medical UniversityRecruitingCerebral Blood Flow | Hyperventilation | Aneurysmal Subarachnoid HemorrhageChina
-
University of AarhusMech-SenseCompleted
-
University Medical Center GroningenCompleted
-
Zhang HaopengCompleted
-
Seoul National University HospitalAjou University School of Medicine; Severance HospitalCompletedInfant, PretermKorea, Republic of